Provectus Biopharmaceuticals will discuss outline of Phase 3 Clinical Trial Of PV-10 To Treat Melanoma on Conference Call

Provectus Biopharmaceuticals, Inc. has announced that it will hold a conference call on Thursday, June 19, 2014, at 4 pm Eastern Daylight Time.

Management will discuss the outline of the Company's proposed Phase 3 study of PV-10 in the treatment of melanoma, developments in the use of PV-10 in other cancer indications, as well as PH-10 and news regarding its use. Management will also discuss its potential plans to monetize its PV-10 and PH-10 assets with various contemplated license and co-development transactions.

Those who wish to participate in the conference call may telephone 877-407-4019 from the U.S. International callers may telephone 201-689-8337 approximately 15 minutes before the call. A webcast will also be available at www.pvct.com.